Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja C Weisel

Showing results (41-50 of 93) with videos related to

Pageof 10
Sort By:
Haematologica|November 27, 2014
Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myelomaKevin W Song, Meletios A Dimopoulos, Katja C Weisel, et al.
Blood Cancer Journal|February 19, 2021
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of lifeEvangelos Terpos, Joseph Mikhael, Roman Hajek, et al.
British Journal of Haematology|February 8, 2021
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trialVania Hungria, Meral Beksac, Katja C Weisel, et al.
Leukemia & Lymphoma|June 9, 2016
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trialsDavid S Siegel, Katja C Weisel, Meletios A Dimopoulos, et al.
Blood Cancer Journal|January 4, 2023
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myelomaElias K Mai, Stefanie Huhn, Kaya Miah, et al.
American Journal of Hematology|July 28, 2025
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular EventsEvangelos Terpos, Suzanne Trudel, María-Victoria Mateos, et al.
Blood Advances|January 19, 2018
Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myelomaMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.
European Journal of Haematology|January 13, 2026
Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data AnalysisNoemi Puig, Xavier Leleu, Hans C Lee, et al.
Cancer Cell|May 5, 2022
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT studyMartin Schönlein, Victoria Wrage, Susanne Ghandili, et al.
Expert Opinion on Investigational Drugs|July 14, 2025
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directionsPaul G Richardson, Elisabeth K O'Donnell, Peter O'Gorman, et al.
Pageof 10

Showing results (41-50 of 93) with videos related to

Sort By:
Pageof 10
Haematologica|November 27, 2014
Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myelomaKevin W Song, Meletios A Dimopoulos, Katja C Weisel, et al.
Blood Cancer Journal|February 19, 2021
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of lifeEvangelos Terpos, Joseph Mikhael, Roman Hajek, et al.
British Journal of Haematology|February 8, 2021
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trialVania Hungria, Meral Beksac, Katja C Weisel, et al.
Leukemia & Lymphoma|June 9, 2016
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trialsDavid S Siegel, Katja C Weisel, Meletios A Dimopoulos, et al.
Blood Cancer Journal|January 4, 2023
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myelomaElias K Mai, Stefanie Huhn, Kaya Miah, et al.
American Journal of Hematology|July 28, 2025
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular EventsEvangelos Terpos, Suzanne Trudel, María-Victoria Mateos, et al.
Blood Advances|January 19, 2018
Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myelomaMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.
European Journal of Haematology|January 13, 2026
Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data AnalysisNoemi Puig, Xavier Leleu, Hans C Lee, et al.
Cancer Cell|May 5, 2022
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT studyMartin Schönlein, Victoria Wrage, Susanne Ghandili, et al.
Expert Opinion on Investigational Drugs|July 14, 2025
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directionsPaul G Richardson, Elisabeth K O'Donnell, Peter O'Gorman, et al.
Pageof 10